Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

Novartis AG (NYSE:NVS) is one of the best defensive stocks to buy, according to Steve Cohen. On September 9, the company confirmed plans to acquire the New York-based pharmaceutical company Tourmaline Bio for $1.4 billion on a fully diluted basis.

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

lucarista/Shutterstock.com

The acquisition paves the way for the company to gain access to pacibekitug, a candidate drug being developed to address systemic inflammation and as a treatment for atherosclerotic cardiovascular disease. The drug is currently in Phase III trials and expected to strengthen its cardiovascular disease portfolio.

The deal is expected to close in the fourth quarter with Tourmaline becoming an indirect wholly-owned subsidiary.

“With no widely adopted anti-inflammatory therapies currently available for cardiovascular risk reduction, pacibekitug represents a potential breakthrough in addressing residual inflammatory risk in ASCVD with a differentiated mechanism of action targeting IL-6,” said Shreeram Aradhye, President, Development and Chief Medical Officer, Novartis.

Novartis AG (NYSE:NVS) is a global healthcare company that focuses on researching, developing, and manufacturing innovative medicines to address significant diseases and improve people’s lives. The company’s core therapeutic areas include cardiovascular, renal and metabolic diseases, oncology, immunology, and neurology.

While we acknowledge the potential of NVS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Wind Power and Solar Stocks to Buy According to Analysts and 10 Best Robinhood Penny Stocks to Invest In.

Disclosure: None. This article is originally published at Insider Monkey.